Therapeutic implications of renal anionic drug transporters

被引:72
作者
Masereeuw, Rosalinde [1 ]
Russel, Frans G. M. [1 ]
机构
[1] Radboud Univ Nijmegen, Dept Pharmacol & Toxicol, Med Ctr, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands
关键词
Renal clearance; Drug transporters; Drug interactions; Transporter polymorphism; Nephrotoxicity; Renal failure; CANCER RESISTANCE PROTEIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONJUGATE EXPORT PUMP; BINDING CASSETTE TRANSPORTERS; PERFUSED RAT-KIDNEY; BASOLATERAL HEPATOCYTE MEMBRANE; PARA-AMINOHIPPURATE TRANSPORT; NUCLEOTIDE ANALOGS CIDOFOVIR; XENOPUS-LAEVIS OOCYTES; DUBIN-JOHNSON SYNDROME;
D O I
10.1016/j.pharmthera.2010.02.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
One of most important functions of the kidney concerns the clearance of endogenous waste products, exogenously administered drugs as well as environmental exposures. In addition to glomerular filtration, active tubular secretion is an efficient mechanism for extracting compounds from the circulation and excreting them into the urinary compartment, and it presents one of the determinants of a drug's pharmacokinetic behavior. The renal proximal tubules are equipped with a range of transporters, which can be roughly divided into a system for organic anions and one for organic cations, each consisting of multiple carriers with overlapping substrate specificities that cooperate in basolateral drug uptake and luminal excretion. Drug transporters are often involved in clinically significant drug-drug interactions, leading to unexpected changes in drug plasma levels. Similar effects may be observed for the interaction of drugs with endogenous substrates and food components. Furthermore, disease states could affect the expression and/or function of transport systems as well, mainly through regulation of gene transcription. Finally, inter-individual variability and gender differences exist in the expression of drug transporters, which affect overall renal drug handling. This review highlights recent knowledge of the renal organic anion system with special reference to the therapeutic implications associated with variations in transporter activity and drug interactions. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:200 / 216
页数:17
相关论文
共 302 条
[1]   Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers [J].
Addison, RS ;
Parker-Scott, SL ;
Eadie, MJ ;
Hooper, WD ;
Dickinson, RG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (9-10) :715-721
[2]   Update on the molecular physiology of organic anion transporters [J].
Ahn, Sun-Young ;
Bhatnagar, Vibha .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2008, 17 (05) :499-505
[3]   Toward a Systems Level Understanding of Organic Anion and Other Multispecific Drug Transporters: A Remote Sensing and Signaling Hypothesis [J].
Ahn, Sun-Young ;
Nigam, Sanjay K. .
MOLECULAR PHARMACOLOGY, 2009, 76 (03) :481-490
[4]   Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment [J].
Aleksunes, Lauren M. ;
Augustine, Lisa M. ;
Scheffer, George L. ;
Cherrington, Nathan J. ;
Manautou, Jose E. .
TOXICOLOGY, 2008, 250 (2-3) :82-88
[5]   THE PHARMACOKINETICS OF FRUSEMIDE ARE INFLUENCED BY AGE [J].
ANDREASEN, F ;
HANSEN, U ;
HUSTED, SE ;
JANSEN, JA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (04) :391-397
[6]   Integrated physiology of proximal tubular organic anion transport [J].
Anzai, N ;
Jutabha, P ;
Kanai, Y ;
Endou, H .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2005, 14 (05) :472-479
[7]  
Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847
[8]   Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux [J].
Bakhiya, N ;
Bahn, A ;
Burckhardt, G ;
Wolff, NA .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2003, 13 (05) :249-256
[9]   ALTERATION IN THE PHARMACOKINETIC DISPOSITION OF CIPROFLOXACIN BY SIMULTANEOUS ADMINISTRATION OF AZLOCILLIN [J].
BARRIERE, SL ;
CATLIN, DH ;
ORLANDO, PL ;
NOE, A ;
FROST, RW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) :823-826
[10]   THE EFFECTS OF INDOMETHACIN AND NAPROXEN ON ZIDOVUDINE PHARMACOKINETICS [J].
BARRY, M ;
HOWE, J ;
BACK, D ;
BRECKENRIDGE, A ;
BRETTLE, R ;
MITCHELL, R ;
BEECHING, NJ ;
NYE, FJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (01) :82-85